v3.22.2.2
Business Combination - Narrative (Details) - USD ($)
$ / shares in Units, $ in Thousands
3 Months Ended 9 Months Ended
May 24, 2022
Sep. 30, 2022
Sep. 30, 2022
Business Acquisition [Line Items]      
Consideration related to Antares closing indebtedness settled by Halozyme $ 19,700    
Antares Pharma, Inc      
Business Acquisition [Line Items]      
Consideration transferred $ 1,045,668    
Consideration transferred, cash paid per acquiree share (in usd per share) $ 5.60    
Consideration related to Antares closing indebtedness settled by Halozyme $ 19,683    
Consideration for seller transaction costs paid by Halozyme 22,906    
Transaction costs   $ 400 $ 20,500
Contingent consideration, liability 130,000 129,800 129,800
Pro forma revenue of acquiree since acquisition date   50,400 69,100
Proforma earnings loss of acquiree since acquisition date   $ 35,500 $ 75,300
Antares Pharma, Inc | Revolving Credit Facility      
Business Acquisition [Line Items]      
Credit facility, maximum borrowing capacity 350,000    
Antares Pharma, Inc | Term Loan Facility      
Business Acquisition [Line Items]      
Credit facility, maximum borrowing capacity $ 250,000